Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A

Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A

SSZSE:301584
17.70
CNY
-0.47
(-2.59%)
0.89EPS
26.93P/E
7.84BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
19.53
24.07
28.22
33.41
43.27
50.24
51.88
46.7
Basic EPS, GAAP
0.64
0.45
0.47
0.49
0.55
0.64
0.72
0.69
Free Cash Flow per Basic Share
1.11
-0.02
-2.09
-1.86
-1.28
0.12
1.78
- -
Dividend per Share
0.09
0.28
0.42
0.4
0.37
0.43
0.34
0.52
Book Value per Share
5.23
5.29
2.63
2.93
3.49
4.14
5.03
5.3
Tangible Book Value per Share
4.99
5.09
2.63
2.81
3.36
4.01
4.93
5.2
Basic Weighted Avg Shares
355
355
355
356
357
357
374
425
Sales/Revenue/Turnover
6,941
8,542
10,024
11,882
15,443
17,923
19,430
19,853
Operating Margin (%)
4.64
3.16
100
3.19
3.17
3.31
3.57
3.7
Depreciation Expense
4
6
110
40
59
84
92
- -
Net Income, GAAP
227
160
167
174
196
228
270
293
Effective Tax Rate (%)
24.43
26.49
23.92
24.1
28.02
27.54
25.77
27.91
Profit Margin (%)
3.28
1.87
1.67
1.47
1.27
1.27
1.39
1.47
Working Capital
1,058
1,074
899
1,029
1,140
1,353
1,992
2,197
LT Debt
- -
35
117
164
133
92
61
66
Total Equity
1,223
1,240
993
1,142
1,431
1,777
2,463
2,624
Return on Invested Capital (%)
- -
13.9
10.71
6.93
5.38
5.19
5.81
- -
Return on Capital (%)
- -
11.97
14.57
12.98
7.97
7.59
5.09
- -
Return on Common Equity (%)
- -
13.56
15.7
17.5
17.06
16.71
14.97
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3,458
3,782
3,688
LT Borrowings
- -
- -
- -
LT Finance Leases
76
48
66
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
421
421
423
Market Capitalization
11,425
8,400
7,844

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
14,724
15,842
16,446
Cash, Cash Equivalents & STI
1,598
1,922
1,854
Accounts Receivable, Net
8,714
9,497
9,521
Inventories
3,348
3,440
3,974
Total Current Liabilities
12,612
13,765
14,249
Payables & Accruals
- -
- -
- -
ST Debt
3,458
3,782
3,688
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
16.64%
38.65%
Free Cash Flow
- -
2,060.51%
1,437.49%
Net Income, GAAP
- -
11.2%
18.1%
Sales/Revenue/Turnover
- -
18.07%
8.41%
Total Cash Common Dividend
- -
7.28%
-16.93%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,988
4,773
- -
- -
17,923
2025
4,516
5,313
- -
4,569
19,430
2026
4,523
5,482
5,279
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.18
- -
- -
0.64
2025
0.14
0.25
- -
0.09
0.72
2026
0.15
0.2
0.25
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.43
2025
0.1
- -
- -
0.07
0.34
2026
0.05
0.25
0.15
- -
- -

Company Description

CEO
Sheng Yong Wu
Full Time Employees
2,115
Sector
Distribution services
Industry
Medical distributors
Address
Shanghai China
IPO Date
Sep 25, 2025
Business
Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. is a China-based medical device supply chain solutions provider and distributor specializing in the procurement, distribution, and hospital-integrated logistics management of medical equipment and consumables. Founded in 2010 and headquartered in Shanghai, China, the company operates as a key healthcare supply chain enterprise within the state-owned Xiamen C&D Group ecosystem, serving hospitals, healthcare providers, and regional sub-distributors across China. The company conducts its operations through direct sales, channel distribution, and in-hospital Supply Processing and Distribution (SPD) services. Its product and service portfolio comprises vascular interventional devices, including coronary drug-eluting stents, balloon dilatation catheters, guidewires, neurovascular intervention products, and peripheral vascular consumables; surgical instruments and operating room supplies, including endoscopic staplers, ultrasonic surgical systems, electrosurgical instruments, and wound management materials; in-vitro diagnostic (IVD) systems, encompassing clinical chemistry reagents, immunodiagnostic assays, molecular diagnostic test kits, and laboratory analyzers; medical equipment, comprising ultrasound imaging systems, patient monitoring systems, and endoscopic visualization systems; consumer healthcare and general hospital consumables; and comprehensive healthcare supply chain management services, including smart SPD warehouse design and management, automated dispensing and RFID tracking cabinets, hospital information and ERP systems integration, cold-chain logistics, regulatory compliance, and consignment inventory management, delivered in partnership with global and domestic medical device manufacturers including Medtronic, Boston Scientific, Abbott, Johnson & Johnson, and Mindray. In recent developments, the company completed its initial public offering (IPO) and listed its Class A shares on the ChiNext board of the Shenzhen Stock Exchange in September 2025 under ticker 301584; accelerated the expansion of its SPD smart hospital service contracts across Tier-III Grade-A medical institutions nationwide; adapted its procurement and distribution models to national volume-based procurement (VBP) healthcare reforms; and executed the scheduled market release of approximately 185 million restricted pre-IPO shares alongside ongoing shareholder dividend distributions.